Most peptide programs are priced by the vial, and most peptide programs underperform for exactly that reason.
Peptide therapy is a longitudinal, titrated, monitored intervention. Pricing it like a retail transaction gives away the clinical work, trains patients to shop on unit price against websites you cannot compete with, and produces revenue that disappears the moment a cheaper vial appears.
Start from cost, not from the competition
Before setting a price, know what a course of therapy actually costs you to deliver:
- Acquisition cost from your pharmacy partner, per course rather than per vial
- Provider time — the initial evaluation, each follow-up, and the between-visit messaging that peptide patients generate
- Staff time for injection teaching, scheduling and refills
- Laboratory work, baseline and interval
- Overhead — room time, storage, cold chain, insurance
The between-visit messaging is the line most practices forget, and on titrated therapies it is substantial. A program that looks profitable on paper often is not once the unbilled messaging is counted.
Why programs beat vials
A program price covers a defined period of care — typically three, six or twelve months — and includes the evaluation, the therapy, the follow-ups, and the labs. It aligns with how the therapy is actually delivered, since titration and maintenance do not happen in a single visit.
It also changes the comparison the patient makes. Against a program that includes clinical oversight, a research-chemical website is not a cheaper version of the same thing; it is a different thing without a clinician attached. That is a comparison you win.
Practices that price this way generally report better adherence too, for the simple reason that a patient who has purchased a course of care behaves differently from one who has purchased a vial.
Memberships, and when they make sense
A monthly membership converts episodic revenue into predictable revenue and suits maintenance-phase patients well. It works when the recurring value is real — ongoing monitoring, adjustments, labs, access — and it fails when it is a payment plan wearing a membership label.
The test is simple: if a patient paused therapy for a month, would the membership still be worth something? If not, it is instalment billing, and patients work that out quickly.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Practice Development & Business Strategies courses — live patients, expert faculty, and ongoing mentorship.
Cash-pay realities
Compounded peptide therapy is not an insurance product, and pretending otherwise creates problems. A few things follow from that:
- Quote the whole course. Surprise costs at month two are the single most common source of complaints in cash programs.
- Separate the evaluation from the therapy. The consultation has value whether or not the patient proceeds, and pricing it that way protects your clinical judgement — a clinician whose income depends on the patient saying yes is in a compromised position.
- Do not discount into unprofitability to match a website. You are not selling the same product.
- Be careful with financing and package language so that discounts do not read as inducements, and so refund terms are written before you need them.
What to watch after launch
Three numbers tell you whether the program works: conversion from consultation to enrolled program, completion of the course as designed, and renewal or maintenance uptake. Revenue per patient is a lagging indicator of those three. If conversion is low the problem is usually the consultation, not the price; if completion is low the problem is usually monitoring and contact frequency.
Frequently asked questions
How should I price peptide therapy?
Price a defined course of care that includes evaluation, therapy, follow-up and labs, built up from your real delivery cost, rather than marking up a vial.
Should peptide therapy be a membership?
Memberships suit maintenance-phase patients where ongoing monitoring has genuine value. They fail when they are instalment billing in disguise.
Can I bill insurance for compounded peptides?
Compounded peptide therapy is generally a cash-pay service. Approved drugs prescribed for approved indications follow ordinary coverage rules.
Should the consultation be free?
Charging for the evaluation protects clinical judgement and filters for patients who want care rather than a product.
How do I compete with online peptide sellers on price?
You do not. You compete on the fact that a clinician evaluated the patient, verified the source, and is monitoring the outcome.
How much should I charge for peptide therapy?
There is no single correct number, and any figure quoted without knowing your costs is guesswork. Build the price from your own delivery cost — acquisition per course, provider and staff time, laboratory work, and the between-visit messaging titrated therapies generate — then price a defined course of care rather than a vial. Practices that price per vial end up competing on unit cost against websites, which is a comparison they lose.
The business module
Module 11 of the Empire Peptide Therapy Certification covers clinic economics and margin per protocol, package and membership design, pharmacy partnership, marketing within advertising rules, and growth — taught by people who run profitable practices. Module 12 covers the legal layer with a healthcare law firm.
